SPC332
Crizanlísúmab
Status:
VeittApplication date:
13.4.2021Application published:
15.5.2021Grant published:
15.12.2022
Max expiry date:
29.11.2032Medicine name:
AdakveoMedicine for children:
No
Timeline
Today
13.4.2021Application
15.5.2021Publication
15.12.2022Registration
29.11.2032Expires
Marketing license
IS authorization number:
EU/1/20/1476/001Date:
6.11.2020
Foreign authorization number:
EU/1/20/1476Date:
28.10.2020
Owner
Name:
Novartis AGAddress:
Lichtstrasse 35, Basel CH
Name:
Oklahoma Medical Research FoundationAddress:
825 N.E. 13th Street, Oklahoma City, OK US
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113 Reykjavík
Patent
Number:
EP2662091